- US-listed companies
- Intra-Cellular Therapies, Inc.
- Income statement
Intra-Cellular Therapies, Inc.ITCI
Market cap
$13.4B
P/E ratio
| 2013/03 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | 3 | 577,301 | 91,364 | 330,702 | 245,837 | - | 60,613 | 23 | 84 | 250 | 464 | 681 |
| Revenue growth (%) | - | - | - | - | |||||||||
| Research & development | - | 23 | 21 | 88 | 94 | 79 | 132 | 89 | 66 | 89 | 135 | 180 | 236 |
| Selling, general & administrative | - | - | - | - | - | - | - | - | - | - | - | - | 504 |
| Operating margin (%) | - | - | |||||||||||
| Operating income | - | -26,266,852 | -30,986,723 | -105,813,996 | -118,258,891 | -102,840,129 | -162,266,768 | -154,011,850 | -231,227,631 | -285,688,125 | -264 | -159 | -117 |
| Operating expenses | - | - | - | - | 119 | 103 | 162 | 154 | 254 | 369 | 514 | 624 | 798 |
| Income before tax | -32,100 | - | - | - | -115,360,595 | -98,834,265 | -155,125,811 | -147,720,578 | -226,992,150 | -284,120,035 | -256 | -139 | -74 |
| Pretax margin (%) | - | - | - | - | -34,883.5 | -40,203.2 | - | -243,711 | -995 | -339 | -102.4 | -29.9 | -10.9 |
| Provision for income taxes | - | 18,000 | 1,600 | 1,600 | 1 | -1,060,851 | 1,600 | 1,600 | 13,513 | 5,631 | 0 | 1 | 0 |
| Effective tax rate (%) | - | - | - | - | |||||||||
| Net income | -32,100 | -26,868,198 | -30,691,460 | -104,793,141 | -116,426,268 | -97,773,414 | -155,127,411 | -147,722,178 | -227,005,663 | -284,125,666 | -256 | -140 | -75 |
| Net income margin (%) | - | - | |||||||||||
| Earnings per share | - | - | - | - | - | - | - | - | - | - | -2.72 | -1.46 | -0.72 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -2.72 | -1.46 | -0.72 |